Summary of the proportion of patients gaining ≥10 letters (BCVA) from baseline to month 12 by study and treatment group.

Not all treatment groups included in the network meta-analysis are presented. Analysis is based on the intention-to-treat population of each study. *Data for READ-2 are proportion of patients who gained ≥10 letters (BCVA) from baseline to month 6. After 6 months, patients in the laser treatment arm could receive ranibizumab, preventing meaningful comparisons between treatment arms at 12 months. BCVA, best-corrected visual acuity; bimonthly, every 2 months; n, number of patients in treatment arm with ≥10 letter increase in BCVA; N, total number of patients in study treatment arm; PRN, pro re nata (as needed).